Evidence map›Paper›PMID 31371807›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2020

Molecular characterization of localized pleural mesothelioma.

Yin P Hung, Fei Dong, Adrian M Dubuc, Paola Dal Cin, Raphael Bueno, Lucian R Chirieac

Open access · bronzeAbstract read
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Diffuse Pleural Mesotheliomas with Genomic Near-Haploidization: A Newly Recognized Subset with Distinct Clinical, Histologic, and Molecular Features.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  8. Review
  9. Solid papillary mesothelial tumor.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022
    Article
  10. Review
  11. Article
  12. Molecular characterization of diffuse malignant peritoneal mesothelioma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020
    Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yin P HungDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA. yphung@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-8568-1591
Fei DongDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
Adrian M DubucDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
Paola Dal CinDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
Raphael BuenoDepartment of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
Lucian R ChirieacDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.ORCID http://orcid.org/0000-0002-4383-6938
Brigham and Women's Hospital · US

Funding

Validation of Prognostic and Diagnostic Molecular Tests in MesotheliomaR01CA120528 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BUENO, RAPHAEL · 2006 to 2021
$4.8M
NCI NIH HHS R01 CA120528
6 · The paper itself

Abstract

Localized pleural mesothelioma is a rare solitary circumscribed pleural tumor that is microscopically similar to diffuse malignant pleural mesothelioma. However, the molecular characteristics and nosologic relationship with its diffuse counterpart remain unknown. In a consecutive cohort of 1110 patients with pleural mesotheliomas diagnosed in 2005-2018, we identified six (0.5%) patients diagnosed with localized pleural mesotheliomas. We gathered clinical history, evaluated the histopathology, and in select cases performed karyotypic analysis and targeted next-generation sequencing. The cohort included three women and three men (median age 63; range 28-76), often presenting incidentally during radiologic evaluation for unrelated conditions. Neoadjuvant chemotherapy was administered in two patients. All tumors (median size 5.0 cm; range 2.7-13.5 cm) demonstrated gross circumscription (with microscopic invasion into lung, soft tissue, and/or rib in four cases), mesothelioma histology (four biphasic and two epithelioid types), and mesothelial immunophenotype. Of four patients with at least 6-month follow-up, three were alive (up to 8.9 years). Genomic characterization identified several subgroups: (1) BAP1 mutations with deletions of CDKN2A and NF2 in two tumors; (2) TRAF7 mutations in two tumors, including one harboring trisomies of chromosomes 3, 5, 7, and X; and (3) genomic near-haploidization, characterized by extensive loss of heterozygosity sparing chromosomes 5 and 7. Localized pleural mesotheliomas appear genetically heterogeneous and include BAP1-mutated, TRAF7-mutated, and near-haploid subgroups. While the BAP1-mutated subgroup is similar to diffuse malignant pleural mesotheliomas, the TRAF7-mutated subgroup overlaps genetically with adenomatoid tumors and well-differentiated papillary mesotheliomas, in which recurrent TRAF7 mutations have been described. Genomic near-haploidization, identified recently in a subset of diffuse malignant pleural mesotheliomas, suggests a novel mechanism in the pathogenesis of both localized pleural mesothelioma and diffuse malignant pleural mesothelioma. Our findings describe distinctive genetic features of localized pleural mesothelioma, with both similarities to and differences from diffuse malignant pleural mesothelioma.

Indexed as

AdultAgedBiomarkers, TumorCyclin-Dependent Kinase Inhibitor p16FemaleGene DeletionGenetic Predisposition to DiseaseHumansMaleMiddle AgedMutationNeurofibromin 2PhenotypePleural NeoplasmsSolitary Fibrous Tumor, PleuralTumor Necrosis Factor Receptor-Associated Peptides and ProteinsBAP1 protein, humanBiomarkers, TumorCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16Neurofibromin 2NF2 protein, humanTRAF7 protein, humanTumor Necrosis Factor Receptor-Associated Peptides and ProteinsTumor Suppressor ProteinsUbiquitin Thiolesterase

Identifiers

PMID31371807
PMCPMC7359734
OpenAlexW2964746205

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.